ClinicalTrials.gov
ClinicalTrials.gov Menu

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02337907
Recruitment Status : Completed
First Posted : January 14, 2015
Results First Posted : November 14, 2018
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Placebo Drug: BI 409306 Drug: Donepezil Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 329 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease
Actual Study Start Date : January 21, 2015
Actual Primary Completion Date : September 15, 2017
Actual Study Completion Date : October 10, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo comparator Drug: Placebo
for blinding purposes

Drug: Placebo
Experimental: BI 409306 dose 1 Drug: Placebo
for blinding purposes

Drug: BI 409306
Experimental: BI 409306 dose 2 Drug: Placebo
for blinding purposes

Drug: BI 409306
Experimental: BI 409306 dose 3 Drug: Placebo
for blinding purposes

Drug: BI 409306
Active Comparator: Active Comparator Donepezil Drug: Placebo
for blinding purposes

Drug: Donepezil
Experimental: BI 409306 dose 4 Drug: Placebo
for blinding purposes

Drug: BI 409306



Primary Outcome Measures :
  1. Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. [ Time Frame: Baseline and 12 weeks ]
    Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB consists of 9 validated components. Raw scores on each of the 9 NTB tests were converted to z-scores using the baseline means and standard deviations (SDs) for each test. The resultant z-scores were averaged to obtain a total z-score, incorporating all 9 NTB tests. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Least Squares Mean is actually an adjusted mean change from baseline.

  2. Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Sister Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) [ Time Frame: Baseline and 12 weeks ]
    Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB consists of 9 validated components. Raw scores on each of the 9 NTB tests were converted to z-scores using the baseline means and standard deviations (SDs) for each test. The resultant z-scores were averaged to obtain a total z-score, incorporating all 9 NTB tests. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. The number of low test scores decreased with higher levels of intellectual abilities. Least Squares Mean is actually an adjusted mean change from baseline.


Secondary Outcome Measures :
  1. Change From Baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Total Score After 12-week Treatment [ Time Frame: Baseline and 12 weeks ]
    Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver. Each item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function. Least Squares Mean is actually an adjusted mean change from baseline.

  2. Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment [ Time Frame: Baseline and 12 weeks ]
    The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Each domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.

  3. Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment [ Time Frame: Baseline and 12 weeks ]
    Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Patients with early signs of dementia of Alzheimer Type
  • Male and female patients with an age of at least 55 years
  • Previous use of Alzheimer's Disease (AD) medications (AChEIs, memantine) is allowed up 3 month prior to screening. Patients who are currently taking AChEIs are eligible as long as they have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the duration of the study. This dose must be consistent with the product label in the concerned country. Patients currently taking memantine are excluded.
  • Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator.
  • Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner etc., guardian or, if applicable, a legal representative)

Exclusion criteria:

  • Cognitive impairment or dementia with any etiology other than Alzheimer's Disease (AD)
  • Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement
  • Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement
  • Any other psychiatric disorders such as schizophrenia, or mental retardation
  • Previous participation in investigational drug studies of mild cognitive impairment/Dementia of Alzheimer Type (DAT) within three months prior to screening. Having received active treatment in any other study targeting disease modification of AD like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed.
  • Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02337907


  Hide Study Locations
Locations
United States, California
California Neuroscience Research
Sherman Oaks, California, United States, 91403
United States, Florida
Bioclinica Research
Orlando, Florida, United States, 32806
Premiere Research Institute
West Palm Beach, Florida, United States, 33407
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
United States, New York
Psychiatry And Alzheimer's Care of Rochester, PLLC
Rochester, New York, United States, 14623
Richmond Behavioral Associates
Staten Island, New York, United States, 10312
United States, North Carolina
ANI Neurology, PLLC, dba Alzheimer's Memory Center
Charlotte, North Carolina, United States, 28270
United States, Oklahoma
Tulsa Clinical Research, LLC
Tulsa, Oklahoma, United States, 74104
United States, Vermont
The Memory Clinic
Bennington, Vermont, United States, 05201
Austria
Private Practice for Psychiatry and Neurology
Wien, Austria, 1130
Belgium
Brussels-UNIV Brugmann -Horta
Brussel, Belgium, 1020
AZ Sint-Blasius
Dendermonde, Belgium, 9200
UNIV UZ Gent
Gent, Belgium, 9000
Mons - UNIV Ambroise Paré
Mons, Belgium, 7000
Canada, Alberta
University of Calgary
Calgary, Alberta, Canada, T2N 4Z6
Canada, British Columbia
Dr. Alexander McIntyre Inc.
Penticton, British Columbia, Canada, V2A 4M4
Canada, Saskatchewan
Pasqua Hospital
Regina, Saskatchewan, Canada, S4T 1A5
Canada
Institut universitaire de geriatrie Sherbrooke
Quebec, Canada, J1J 3H5
France
HOP Pellegrin
Bordeaux, France, 33076
HOP Bocage
Dijon, France, 21079
HOP Timone
Marseille, France, 13385
HOP Gui de Chauliac
Montpellier, France, 34295
HOP Nord Laënnec
Nantes, France, 44093
HOP La Pitié Salpêtrière
Paris, France, 75651
HOP Jean Bernard, Géria, Poitiers
Poitiers, France, 86021
Germany
Praxis Dr. med. Volker Schumann
Berlin, Germany, 10245
emovis GmbH
Berlin, Germany, 10629
St. Josef- und St. Elisabeth-Hospital gGmbH
Bochum, Germany, 44791
Neuro Centrum Science GmbH
Erbach, Germany, 64711
AFL Arzneimittelforschung Leipzig GmbH
Leipzig, Germany, 04107
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany, 55131
Zentralinstitut für seelische Gesundheit
Mannheim, Germany, 68159
Universitätsklinikum Ulm
Ulm, Germany, 89081
Neurologie und Psychiatrie / Psychotherapie
Westerstede, Germany, 26655
Italy
P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna
Bologna, Italy, 40139
Azienda Ospedaliera Careggi
Firenze, Italy, 50134
Azienda Ospedaliera di Parma
Parma, Italy, 43126
Netherlands
Jeroen Bosch Ziekenhuis-Hertogenbosch
's-HERTOGENBOSCH, Netherlands, 5223 GZ
Brain Research Center
Amsterdam, Netherlands, 1081 GN
Poland
Podlassian Center of Psychogeriatry, Bialystok
Bialystok, Poland, 15-756
Mental Health Center Biomed
Kielce, Poland, 25-411
Non-Public Outpatient Clinic Neuromed M. i M. Nastaj
Lublin, Poland, 20-064
Inst. of Rural Health, Spec. Outp. Clin. & Rural Occup. Dis.
Lublin, Poland, 20-090
Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners
Poznan, Poland, 61-853
Medical Center Senior
Sopot, Poland, 81-855
EUROMEDIS Sp. z o.o., Szczecin
Szczecin, Poland, 70-111
Reg. Specialist Hospital Wroclaw, Research & Develop. Center
Wroclaw, Poland, 51-124
Portugal
Hospital Fernando Fonseca, EPE
Amadora, Portugal, 2700-276
Hospital de Braga-Escala Braga
Braga, Portugal, 4710-243
CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
Coimbra, Portugal, 3000-075
Hospital Senhora Oliveira Guimarães,EPE
Guimarães, Portugal, 4835-044
CHLO, EPE - Hospital Egas Moniz
Lisboa, Portugal, 1349-019
Hospital Beatriz Ângelo
Loures, Portugal, 2674-514
ULSM, EPE - Hospital Pedro Hispano
Matosinhos, Portugal, 4454-509
Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião
Santa Maria da Feira, Portugal, 4520-211
United Kingdom
Royal United Hospital
Bath, United Kingdom, BA1 3NG
Ninewells Hospital & Medical School
Dundee, Scotland, United Kingdom, DD19SY
West Devon (Tavistock) CMHT & Memory Clinic (EDI)
Ivybridge, United Kingdom, PL219AB
Re-Cognition Health
Plymouth, United Kingdom, PL6 8BT
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  Study Documents (Full-Text)

Documents provided by Boehringer Ingelheim:
Statistical Analysis Plan  [PDF] June 13, 2017
Study Protocol  [PDF] February 23, 2017


Additional Information:
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02337907     History of Changes
Other Study ID Numbers: 1289.7
2013-005040-28 ( EudraCT Number )
First Posted: January 14, 2015    Key Record Dates
Results First Posted: November 14, 2018
Last Update Posted: November 14, 2018
Last Verified: October 2018

Additional relevant MeSH terms:
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents